Pneumococcal vaccine gets go-ahead for infant trial
The US Food and Drug Administration (FDA) has cleared Vaxcyte’s infant Investigational New Drug (IND) application for VAX-24, its 24-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease (IPD). The company plans to initiate the infant Phase II study in the second… Read More